Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC INDEX(TM) Updated thru DEC 2009
    - OnBioVC 2009 Year-in-Review, now available
    - OnBioVC 1Q10 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • business strategy life science

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.

Heptares Therapeutics (United Kingdom) a discovery-stage company focused on small-molecule drugs targeting G-protein-coupled receptors whose lead indication is Parkinson’s, closed a $29.9M Series A financing. Participants include Clarus Ventures, MVM Life Science Partners and Novartis Ventures Option Fund.

Satori Pharmaceuticals (Cambridge, MA) an early-stage neuroscience company focused on the discovery and development of therapies for Alzheimer’s, Parkinson’s disease and other neurodegenerative disorders closed a $22M Series B financing. Participants include InterWest Partners, Prospect Venture Partners, New Enterprise Associates and PureTech Ventures.

  

to top of page...